butamben

Small moleculeexperimental

Butamben is a local anesthetic. It is the ester of 4-aminobenzoic acid and butanol. It is one of three components in the topical anesthetic Cetacaine. The onset of Cetacaine-produced anesthesia is rapid (approximately 30 seconds) and the duration of anesthesia is typically 30-60 minutes, when used as directed. This effect is due to the rapid onset, but short duration of action of Benzocaine coupled with the slow onset, but extended duration of Tetracaine HCI and bridged by the intermediate action of Butamben. — NCATS

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 1, 2018 (NCT03402321)

Timeline

2020s

Jan 1, 2021
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Pain

Studied for

Mechanism of action

Transient receptor potential cation channel subfamily A member 1INHIBITOR
TRPA1 inhibitor
Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).
- Transient receptor potential cation channel subfamily A member 1 (TRPA1) ↗
Transient receptor potential cation channel subfamily V member 4INHIBITOR
TRPV4 inhibitor
Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).
- Transient receptor potential cation channel subfamily V member 4 (TRPV4) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CCCCOC(=O)C1=CC=C(N)C=C1

Mol. weight: 193.2423 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

abbott-34842
abbott-34842
abbott brand of butamben picrate
butamben
butamben
butamben
butamben
butamben
butamben
butamben
butamben
butambene
butamben picrate
butamben picrate
butamben picrate
butanylcaine
butesin
butesin
butesin
butesin
butesine
butoform
butyl 4-aminobenzoate
butyl aminobenzoate
butyl aminobenzoate
butyl aminobenzoate
butyl aminobenzoate
butylcaine
butylcaine
n-butyl-p-aminobenzoate
zyljectin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06456060	Phase 1	Jun 1, 2024	Watim Medical
NCT06144983	Phase 4	Feb 1, 2022	University of Baghdad
NCT05334745	Phase 1	Dec 1, 2021	Cairo University
NCT03402321	Phase 4	Apr 1, 2018	Cairo University

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Cairo University	Academic/Hospital	2	2	2	2018
University of Baghdad	Academic/Hospital	1	1	1	2022
Watim Medical	Academic/Hospital	1	1	1	2024

3 organizations

Page 1 / 1